Top 5 Building Product Stocks To Watch Right Now

Mixed housing data, among rising interest rates are already hurting shares of companies related to the housing market. What�� more, higher vitality and uncertainty related to the geopolitical risk in Syria affect the global financial markets. Let�� analyze three stocks of companies directly related to the housing market through wood building products they make.

Highly Dependent on General Market Conditions And Particular Customers

Universal Forest Products Inc. (UFPI) is a holding company that provides capital, management and administrative resources to subsidiaries that design, manufacture and market wood and wood-alternative products. It currently consumes about 7 percent of North American softwood lumber production per year.

On the bright side, an increase in home improvement spending and national housing starts is likely to benefit the company. Management is focusing its energy on business expansion and new product initiatives, to gain market share. Last November they purchased Nepa Pallet assets that strengthened the company�� position in the Northwest region of the US. What�� more, in January they have also acquired Custom Caseworks that enabled growth of industrial business through new product offerings.

Top 5 Building Product Stocks To Watch Right Now: Banca Monte dei Paschi di Siena SpA (BMPS)

Banca Monte dei Paschi di Siena SpA is an Italy-based company engaged in the banking sector. It provides traditional banking services, asset management and private banking, including life insurance, pension funds and investment trusts. It operates though three business segments. The Retail Banking segment covers consumer lending, insurance, provision of financial and non-financial services to retail customers, wealth management, tax planning, financial advisory and planning for private customers. The Corporate Banking division oversees the Group's business strategies targeted to small and medium enterprises, institutions and large corporate for which it offers leasing, factoring, lending and financial products, among others. The Corporate Center segment includes the cancellation of intergroup entries, treasure, governance and support functions. In January 2014, the Company completed the sale of its entire shareholding in Sorin SpA, equal to approximately 5.7%. Advisors' Opinion:

• [By Corinne Gretler]

  Kesko Oyj, Finland�� biggest publicly traded retailer, rallied 9 percent. Banca Monte dei Paschi di Siena SpA (BMPS) added 2 percent as Italy�� third-largest lender set out a plan to return to profit after cutting costs and raising capital as part of its restructuring plan. Speedy Hire Plc sank the most since 2009 after the construction-equipment leasing company said it found evidence of false accounting at one of its units.

Top 5 Building Product Stocks To Watch Right Now: Insignia Systems Inc.(ISIG)

Insignia Systems, Inc. markets in-store advertising products, programs, and services to consumer packaged goods manufacturers and retailers in the United States and internationally. The company focuses on providing in-store services through the Insignia Point-Of-Purchase Services (POPS) in-store advertising program. Its Insignia POPSign program is a national account-specific in-store shelf-edge advertising program, which allows manufacturers to deliver vital product information to consumers at the point-of-purchase together with each retailer?s store-specific prices. The company also offers Stylus software, which allows retailers to create signs, labels, and posters by manually entering the information or by importing information from a database; and laser printable cardstock and vinyl labels, including adhesive and non-adhesive supplies in various colors, sizes, and weights to retailers for their in-store signage and shelf-edge product information needs. The company dire ctly markets its Insignia POPSign program to food and drug manufacturers and retailers; and markets its Stylus software through resellers. Insignia Systems, Inc. was founded in 1990 and is based in Minneapolis, Minnesota.

Advisors' Opinion:

• [By CRWE]

  MINNEAPOLIS- October 26, 2013 -(CRWE Press Release) -Insignia Systems, Inc. (NASDAQ:ISIG) announced that it intends to hold a conference call on Wednesday, October 30 at 4:00 PM Central Time to discuss the Company’s financial performance for the third quarter of 2013, which will be released Wednesday, October 30 at 3:05 PM Central Time.

  Participants may access the live call by dialing the toll-free number 877-268-1608 and provide Conference ID 98094181. Please be sure to call in about 5-10 minutes before the call is scheduled to begin. Audio replay will be available approximately two hours after the call until November 6, 2013 by dialing 855-859-2056 and referencing Conference ID 98094181. The audio recording will also be archived on the Company�� website approximately two days after the call until November 30, 2013. Financial information to be provided in the conference call, as well as information pertaining to the Company�� past financial performance, may be accessed on the Investor Relations page of the Company�� website at www.insigniasystems.com.

  Insignia Systems, Inc. is a developer and marketer of in-store media solutions, programs and services to retailers and consumer goods manufacturers. Through its Point-Of-Purchase Services (POPS) business, Insignia inspires shoppers and delivers value by providing at-shelf advertising solutions in over 13,000 chain retail supermarkets, over 1,700 mass merchants and 7,000 dollar stores. Through the nationwide POPS network, over 200 major consumer goods manufacturers, including Armour-Eckrich, General Mills, Hormel, Kellogg Company and Nestl茅, have taken their brand messages to the point-of-purchase. For additional information, contact (888) 474-7677, or visit the Insignia website at www.insigniasystems.com.

  Contact

Top 5 Healthcare Technology Stocks To Buy Right Now: CombiMatrix Corporation(CBMX)

CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the fields of genetic analysis and molecular diagnostics in the United States. The company, through its wholly owned subsidiary, CombiMatrix Diagnostics, operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, and other laboratories in two primary areas, including prenatal and postnatal developmental disorders, and oncology. It offers a suite of developmental disorder array tests on the prenatal and postnatal application of array-comparative genomic hybridization in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company also provides DNAarray?Heme Profile test to address various common hematological malignancies, including chronic lymphocytic leukemia; DNAarray?HER2 PRO test for breast cancer; and DNAarray?Tumor Profile test for the analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. In addition, it focuses on developing a series of drug compounds to address various oncology-related diseases. CombiMatrix Corporation was founded in 1995 and is based in Irvine, California.

Advisors' Opinion:

• [By Wallace Witkowski]

  Also, shares of Combimatrix Corp. (CBMX) rose 7.5% to $2.73 in moderate volume late Friday following a Securities and Exchange Commission filing showing Longwood Capital Partners acquired a 5.1% stake in the microcap molecular diagnostics company.

Top 5 Building Product Stocks To Watch Right Now: California Grapes International Inc (CAGR)

California Grapes International, Inc., formerly China Food Services, Corp., incorporated in 1992, conducts its primary business operations as an importer, exporter and distributor of staple, organic, specialty, and gourmet foods and beverages, catering to the Asian Pacific Rim. The Company owns and operates Golden Dragon Food & Beverage Import & Export Company of Hong Kong, Ltd. (GDHK) in central Hong Kong and Beijing Flying Golden Dragon International Trading Co., Ltd. in China (BFGD). Golden Dragon Holdings, Inc. has agreements with the United State food manufacturers. It acts as a buying agent for GDHK, negotiating vendor contracts and services with the United States food and beverage industry partners.

The Company focuses to offer wholesale food distribution to grocery chains and independent food stores throughout China. The Company focuses on purchasing goods directly from manufactures in the United States, Latin America and Europe, and distributes these products to distributors, grocery stores, supermarkets and hypermarkets throughout China.

Advisors' Opinion:

• [By ovenerio]

  As we can see in the next chart, the stock price has an upward trend in the five-year period. If you had invested $10,000 five years ago, today you could have $23,305, which represents a 18.4% compound annual growth rate (CAGR).

• [By ovenerio]

  As we can see in the next chart, the stock price has an upward trend in the five-year period. If you had invested $10.000 five years ago, today you could have $18.598, which represents a 13.2% compound annual growth rate (CAGR).

• [By Omar Venerio]

  As we can see in the next chart, the stock price has an upward trend in the five-year period. If you had invested $10,000 five years ago, today you could have $17,891, which represents a 12.3% compound annual growth rate (CAGR).

Top 5 Building Product Stocks To Watch Right Now: Pacific Coast Oil Trust (ROYT)

Pacific Coast Oil Trust is a statutory trust formed by Pacific Coast Energy Company LP (PCEC) to own interests in the Underlying Properties. As of December 31, 2011, the Underlying Properties consisted of the proved developed reserves on the Underlying Properties, which it refers to as the Developed Properties, and all other development potential on the Underlying Properties, which it refers to as the Remaining Properties. The Underlying Properties are located in California in the Santa Maria and Los Angeles Basins. PCEC produces oil and natural gas from its Orcutt properties in the Santa Maria Basin. The production in the Orcutt oilfield is produced from formations utilizing conventional production methods.

PCEC is engaged in the production and development of oil and natural gas from properties located in California. As of December 31, 2011, PCEC held interests in approximately 276 gross (215 net) producing wells, and had proved reserves of approximately 34.1 million barrels of oil equivalent. The Underlying Properties consist of producing and non-producing interests in oil units, wells and lands located onshore in California in the Santa Maria Basin, which contains PCEC�� Orcutt properties, and the Los Angeles Basin, which contains PCEC�� West Pico, East Coyote and Sawtelle properties. As of December 31, 2011, there were 37 producing wells and six waterflood injection wells in the West Pico Unit. West Pico also includes three wells held by the Stocker JV, a joint venture between PCEC and PXP.

Advisors' Opinion:

• [By Rich Duprey]

  Perpetual royalty trust�Pacific Coast Oil Trust (NYSE: ROYT  ) announced yesterday its July distribution of $0.15721�per unit. The amount of the trust's monthly distributions will fluctuate depending on the proceeds it receives from its owner, Pacific Coast Energy, as a result of actual production volumes, oil and gas prices, and development expenses.� The current distribution relates to net profits and overriding royalties generated during May 2013.

• [By Robert Rapier]

  We do follow them, but generally don�� like the risk/reward ratio for most MLP investors. I have had some conversations with investors who were chasing the 12-14% yields on these trusts without really appreciating the underlying risks. As you note,�Pacific Coast Oil Trust�(NYSE: ROYT) is near its 52-week low after declining by 25% over the past year. Those high yields provide little consolation given that sort of downside risk.

Top India Companies To Invest In Right Now

INDIA

India's Opposition Wins Election by Landslide Election Result Pushes Rupee and Sensex Higher New Indian Government Will Inherit Slow Output and High Inflation Indian Central Bank Could Come Under Pressure From New Government

The largest democracy in the world finished its five week long election process. The final results will be a surprise to no one as the BJP had a strong campaign. In January polls favoured them to win a majority after the party's leader was hitting all the right notes on the campaign trail. The opposition is on track to win by a landslide and score a majority in the lower house.

The optimism surrounding the potential BJP win aligned with a strong market rally that pushed the currency and the stock market higher. The INR appreciated the whole week to finish at 58.55 after starting the week close to 60 USD/INR. The expectation is for the new government to deliver on its promise of economic growth. Narendra Modi the BJP's candidate has promised a strong economic revival. The main challenge will be to turn campaign rhetoric against the political establishment into a reality for all Indians.

Top India Companies To Invest In Right Now: Infosys Technologies Limited(INFY)

Infosys Ltd. provides information technology (IT) and consulting services worldwide. It offers IT services, such as application, architecture, independent validation and testing, information management, infrastructure, packaged application, SOA, systems integration, and knowledge services; product engineering services, manufacturing process and plant solutions, and product lifecycle management services; and consulting services in the areas of information and technology strategies, product innovation, next generation commerce, process excellence, and learning and complex change. The company also provides business process outsourcing solutions in the areas of business platforms, customer service outsourcing, finance and accounting, human resources outsourcing, legal services, sales and fulfillment, and sourcing and procurement outsourcing. In addition, it offers collaborative analytics solutions; digital consumer platform; Finacle universal banking solution; iProwe, a Web ac cessibility assessment product; mConnect, a real-time enterprise middleware; and research and analytical support services. Further, the company offers unified communications and collaboration solution that streamlines business processes between employees, customers, and suppliers; iTransform that helps healthcare organizations accelerate transition to new platforms; and supply chain visibility and collaboration product suite. It serves aerospace and defense, airlines, automotive, banking, capital markets, communication services, consumer packaged goods, manufacturing, education, energy, healthcare, high technology, hospitality and leisure, insurance, life sciences, logistics and distribution, publishing, resources, utilities, and retail industries. Infosys Ltd. has a strategic partnership with Alstom SA. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Ltd. on June 16, 2011. Infosys Ltd. was founded in 1981 and is headquartered i n Bengaluru, India.

Advisors' Opinion:

• [By Laura Brodbeck]

  Next week investors will be waiting for several key earnings reports including Wells Fargo & Company (NYSE: WFC), Alcoa (NYSE: AA), Family Dollar Stores (NYSE: FDO) and Infosys Limited (NASDAQ: INFY).

• [By Robert Martin]

  Infosys (INFY), Housing Development Finance and Reliance Industries LTD are the top three holdings, with weightings between 8% and 10.5%. Of course, just about any India ETF will have a heavy� allocation to Infosys and Reliance. However, INDA dedicates a lower percentage to energy than some of the alternatives, and instead leans more on IT and consumer spending.

Top India Companies To Invest In Right Now: Stewart Information Services Corporation(STC)

Stewart Information Services Corporation provides title insurance and related information services required for settlement by the real estate and mortgage industries. It operates in two segments, Title Insurance-Related Services and Real Estate Information. The Title Insurance-Related Services segment offers services that include searching for and examining documents, such as deeds, mortgages, wills, divorce decrees, court judgments, liens, paving assessments, and tax records, as well as provides titles insurance for residential and commercial properties, undeveloped acreage, farms, ranches, and water rights. This segment serves attorneys, builders, developers, home buyers and home sellers, lenders, and real estate brokers. The Real Estate Information segment offers products and services, which primarily include lender services, title technology, foreign and domestic government services, mapping, title information, Internal Revenue Code Section 1031 tax-deferred property e xchanges, pre-employment services, and online filing and transaction management. Its customers include mortgage lenders and servicers, mortgage brokers, mortgage investors, government entities, commercial and residential real estate agents, land developers, builders, title insurance agencies, and others interested in obtaining property information, as well as accountants, attorneys, investors, and employers. The company has operations primarily in the United States, Canada, the United Kingdom, central Europe, Mexico, central America, and Australia. Stewart Information Services Corporation was founded in 1893 and is based in Houston, Texas.

Advisors' Opinion:

• [By Ben Levisohn]

  Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, the�Navigators Group�(NAVG) has fallen 1.4% to $54.78 and HCI Group�(HCI) has gained 1% to $38.16.

10 Best Wireless Telecom Stocks To Buy Right Now: Tata Motors Ltd(TTM)

Tata Motors Limited, an automobile company, engages in the manufacture and sale of commercial and passenger vehicles primarily in India. The company offers cars, utility vehicles, trucks, buses and coaches, and defense vehicles, as well as develops electric and hybrid vehicles for personal and public transportation. It also involves in distributing and marketing cars; and financing the vehicles sold by the company. In addition, the company engages in the provision of engineering and automotive solutions, as well as machine tools and factory automation solutions; construction equipment manufacturing; automotive vehicle components manufacturing and supply chain activities; tooling and plastic and electronic components for automotive and computer applications; and automotive retailing and service operations. It offers its products and services through its dealership, sales, services, and spare parts network. The company also markets its commercial and passenger vehicles in Eu rope, Africa, the Middle East, South East Asia, South Asia, and South America. The company was formerly known as Tata Engineering and Locomotive Company Limited and changed its name to Tata Motors Limited in July 2003. Tata Motors Limited was founded in 1945 and is based in Mumbai, India.

Advisors' Opinion:

• [By Sophia Yan]

  Shares of Tata Motors (TTM) tumbled almost 5% in morning trading in Mumbai as investors reacted to news of Slym's death. Tata Motors also owns Jaguar and Land Rover brands.

Top India Companies To Invest In Right Now: Dr. Reddy's Laboratories Ltd(RDY)

Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Advisors' Opinion:

• [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
  
  Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade.
• [By Seth Jayson]

  Dr. Reddy's Laboratories (NYSE: RDY  ) reported earnings on May 14. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share.

• [By Rich Duprey]

  Following FDA approval of its abbreviated new drug application, or ANDA,�Dr. Reddy's Laboratories (NYSE: RDY  ) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal.�

• [By Monica Gerson]

  Dr. Reddy's Laboratories (NYSE: RDY) is expected to report its Q4 earnings at $0.52 per share.

  YuMe (NYSE: YUME) is estimated to post a Q1 loss at $0.15 per share on revenue of $35.36 million.

Top India Companies To Invest In Right Now: Sify Technologies Limited(SIFY)

Sify Technologies Limited provides enterprise and consumer Internet services primarily in India. The company offers various corporate network/data services comprising e-commerce and network connectivity solutions, such as end-to-end services network, application, and security services; voice origination and termination services; co-location and managed hosting services; and system integration services for data centre build, hardware distribution, security solutions, and turnkey projects. It also provides application services, including SLEMS and Microsoft Exchange messaging platforms; I-test for online assessment and LiveWire, which enable management of training processes across the organization; document management system for the management of documents electronically; and Forum, a forward supply chain solution. In addition, the company operates e-Ports that offer browsing, chat, email, gaming, utility bill payment, travel ticketing, hotel booking, mobile recharge, Intern et telephony, and online share trading services; and portals, which provide news, views, reviews, interactions, and services in the areas of movies, sports, finance, food, videos, astrology, online games, shopping, and travel, as well as offers content offerings and broadband services. Further, it provides infrastructure management services, such as network management, datacenter and helpdesk outsourcing, desktop and storage outsourcing, IT security outsourcing, LAN and WAN outsourcing, database and telecom outsourcing, and application monitoring and management services to automotive, chemical, media, and financial enterprises; and virtualization design, integration, and deployment services for servers, storage, networks, and end user clients. Sify has approximately 1,278 e-Ports in 200 towns and cities; and serves 1,06,000 broadband subscribers through 1500 cable TV Operators. The company, formerly known as Sify Limited, was founded in 1995 and is based in Chennai, India. Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Technology stocks gained Tuesday, with Ku6 Media Co (NASDAQ: KUTV) leading advancers. Among leading tech stocks, gains came from Rubicon Technology (NASDAQ: RBCN), Bitauto Holdings (NYSE: BITA) and Sify Technologies (NASDAQ: SIFY). Utilities shares dropped by 0.11 percent in the US market today.

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Technology stocks gained Tuesday, with Ku6 Media Co (NASDAQ: KUTV) leading advancers. Among leading tech stocks, gains came from Rubicon Technology (NASDAQ: RBCN), Bitauto Holdings (NYSE: BITA) and Sify Technologies (NASDAQ: SIFY).

Hot Quality Stocks To Invest In Right Now

Hot Quality Stocks To Invest In Right Now: Sensient Technologies Corp (SXT)

Sensient Technologies Corporation, incorporated on December 07, 1882, is a global manufacturer and marketer of colors, flavors and fragrances. Sensient uses advanced technologies at facilities around the world to develop specialty food and beverage systems, cosmetic and pharmaceutical systems, inkjet and specialty inks and colors, and other specialty and chemicals. The Company's customers include international manufacturers representing some of the Known brands. The Company operates in two segments: Flavors & Fragrances Group and the Color Group. The Asia Pacific and the China Groups are included in the Corporate & Other category, along with the Company's corporate expenses. The Company's principal products include: flavors, flavor enhancers and bionutrients; fragrances and aroma chemicals; dehydrated vegetables and other food ingredients; natural and synthetic food and beverage colors; cosmetic and pharmaceutical colors and additives; and technical colors, inkjet colo rs and inks, and specialty dyes and pigments.

Flavors & Fragrances Group

The Company is a developer, manufacturer and supplier of flavor and fragrance systems for the food, beverage, pharmaceutical, personal care and household-products industries. The Company's flavor formulations are used in consumer products. Under the unified brand names of Sensient Flavors, Sensient Dehydrated Flavors and Sensient Fragrances, the Company is a supplier to multinational companies. The Flavors & Fragrances Group produces flavor and fragrance products, which impart a taste, texture, aroma and/or other characteristics to a range of consumer and other products. It includes the Company's dehydrated flavors business, which produces ingredients for food processors. The products are systems products, including flavor-delivery systems, and compounded a! nd blended products. In addition, the Company is engaged in selected ingredient products, such as essential oils, natu ral and synthetic flavors, and aroma chemicals. The Company ! serves food and non-food industries. In food industries, markets include savory, beverage, dairy, confectionery and bakery flavors. In non-food industries, the Company supplies fragrance products to the personal and home-care markets and supplies flavor products to the pharmaceuticals market.

Operating through the Company's Sensient Dehydrated Flavors business, the Company is produces dehydrated onion and garlic products in the United States. The Company is also producers and distributors of chili powder, paprika, chili pepper and dehydrated vegetables, such as parsley, celery and spinach. Domestically, the Company sells dehydrated products to food manufacturers for use as ingredients and also for repackaging under private labels for sale to the retail market and to the food service industry. In addition, Sensient Dehydrated Flavors is dehydrators of specialty vegetables in Europe. The Flavors & Fragrances Group operates through the Company's subsidiaries Sens ient Flavors LLC and Sensient Dehydrated Flavors LLC. The Company's principal manufacturing plants are located in California, Illinois, Indiana, Michigan, Wisconsin, Belgium, Canada, the People's Republic of China, France, Germany, Italy, Mexico, the Netherlands, Spain and the United Kingdom.

Color Group

The Company is a developer, manufacturer and supplier of colors for businesses globally. The Company provides natural and synthetic color systems for use in foods, beverages and pharmaceuticals; colors and other ingredients for cosmetics and pharmaceuticals, and technical colors for industrial applications and digital imaging. The Company sells its synthetic and natural colors to domestic and international producers of beverages, bakery products, processed foods, confections, pet foods, cosmetics and pharmaceuticals. The C! ompany al! so makes inkjet inks and other dyes and pigments used in a variety of non-food applications.

The Color Group operates through the Company's subsidiary Sensient Col! ors LLC. ! Its principal manufacturing plants are located in California, Missouri, New Jersey, Brazil, Canada, Mexico, France, Germany, Hungary, Italy, Switzerland and the United Kingdom. The Color Group operates under trade names of Sensient Food Colors (food and beverage colors); Sensient Pharmaceutical Coating Systems (pharmaceutical colors and coatings); Sensient Cosmetic Technologies (cosmetic colors and ingredients and systems). and Sensient Industrial Colors (including paper colors; industrial colors for plastics, leather, wood stains, antifreeze and other uses; inkjet colors and inks; specialty inks, and display imaging).

Asia Pacific and China Groups

The Asia Pacific Group and the China Group focus on marketing the Company's diverse product line in the Pacific Rim under the Sensient name. Through these operations, the Company offers a range of products from its Flavors & Fragrances Group and Color Group, as well as products developed by regional technical teams to appeal to local preferences. Sales, marketing and technical functions are managed through the Asia Pacific Group's headquarters in Australia. Manufacturing operations are located in Australia, Japan, New Zealand and the Philippines. The Asia Pacific Group maintains offices for research and development, as well as sales, in India, Indonesia, Korea, Singapore and Thailand.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Sensient Technologies (NYSE: SXT  ) , whose recent revenue and earnings are plotted below.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-quality-stocks-to-invest-in-right-now.html

5 Best Quality Stocks To Own For 2014

Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Also check out: Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks, and Stocks that Diamond Hill Capital keeps buying

Currently 0.00/512345

Rating: 0.0/5 (0 votes)

Top 10 Valued Companies To Watch In Right Now: View Systems Inc (VSYM)

View Systems, Inc. (View Systems), incorporated on July 25, 2003, develops, produces and markets computer software and hardware systems for security and surveillance applications. The Company has penetrated four market segments for this product: correctional facilities, judicial facilities, probation offices and federal facilities in the Mid-Atlantic States, the West Coast and the South. The Company�� products and services include ViewScan Concealed Weapons Detection System, Multi-Mission Mobil Video (MMV), ViewMaxx Digital Video System, Additional Applications and Integration of ViewScan and ViewMaxx, the MINI, Network Services, FiberXpress, Inc., Visisys Ltd. and Training and Service Programs.

ViewScan Concealed Weapons Detection System

ViewScan is sold under the name Secure Scan, is a walk-through concealed weapons detector, which uses data sensing technology to pinpoint the location, size and number of concealed weapons. This walk-through portal is controlled by a master processing board and a personal computer based unit which receives magnetic and video information and combines it in a manner that allows the suspected location of the weapon to be stored electronically and referenced. ViewScan products are distributed in three basic configurations; stand-alone units, portable units and integrated door systems. ViewScan is designed to overcome the traditional shortcomings of electromagnetic induction scanners.

Multi-Mission Mobil Video

The MMV is a lightweight, wireless camera system housed in a tough, waterproof body. The camera system sends back real-time images to a computer or video monitor at the command post located outside the exclusion zone or containment area. The MMV also uses an Extension Link which is a separate transmitter and receiving system that increases the operating range of the MMV.

The Company has incorporated a video encryption feature that allows first responders to transmit on-scene video to the command post! without the data being intercepted by unwanted parties. The MMV is fully deployed by one person in a stand-alone configuration in less than 10 minutes. The system is battery operated and can operate for eight continuous hours using one set of spare camera batteries.

ViewMaxx Digital Video System

ViewMaxx is a high-resolution, digital video recording and real-time monitoring system. This system can be scaled to meet a specific customer's needs by using anywhere from one camera up to 32 surveillance cameras per each ViewMaxx unit. The system uses a video capture card recording which translates closed-circuit television analog video data (a format normally used by broadcasters for national television programs) to a computer readable digital format to be stored on direct access digital disk devices rather than the conventional television format of video tape. ViewMaxx offers programmable recording features that can eliminate the unnecessary storage of non-critical image data.

Additional Applications and Integration of ViewScan and ViewMaxx

The Company offers integration of other products with ViewScan or ViewMaxx. Its product can be interfaced with ViewScan and/or ViewMaxx to limit individual access to an area. ViewScan and/or ViewMaxx can be coupled with magnetic door locks to restrict access to a particular area. It also offers a central monitoring or video command center for ViewScan or ViewMaxx products.

The MINI

The MINI (Mobile Intelligent Network Informer) is a portable, wireless watchdog communication device that checks for intrusion into uninhabited areas such as foreclosed houses, storage spaces and vacation homes. The MINI senses motion and sends text messages to a user's cell phone. Property and remote assets may be guarded by this device that requires no plug-in electricity, no physical phone line and no monitoring service. The MINI runs on batteries and one configuration of the system can even send a photo of the in! truder to! the user's cell phone. Camera settings can be controlled and changed via short message service (SMS) commands. It licenses the MINI from its manufacturer and acts as a distributor.

Network Services

View Systems Inc. Network Services group supplied integrated electronic security and control systems. It supplied for commercial and industrial applications throughout the Mid Atlantic area.

FiberXpress, Inc.

FiberXpress, Inc. sells specialist data network related products. It sells its products through its Internet Website.

Visisys Ltd.

During the year ended December 31, 2011, there were no revenues from this partnership. The Company's partnership with Visisys, Ltd. has been terminated.

Training and Service Programs

The Company offers support services for our products, which includes on site consulting/planning with customer architect and engineers; installation and technical support; installation and technical support, and cand. The Company's family of products offers government and law enforcement agencies, commercial security professionals, private businesses and residential consumers an enhanced surveillance and detection capacity. Its ViewScan products and technology can be used where there is a temporary requirement for real-time weapons detection devices in areas where a permanent installation is prohibitive or impractical.

A primary market for the Company's ViewScan portal is federal and state government courthouses, county and municipal buildings, and correctional facilities. The Company has installed its ViewScan weapons detection products in a variety of court house situations. The MMV product's market includes National Guard units and first response agencies such as fire, police, SWAT, and homeland security response teams.

The Company competes with Ranger Security Scanners, Inc., Garrett Electronics, Inc., CEIA SpA, Sensormatic Corporation, NICE Systems, Ltd. and Inte! gral Syst! ems.

Advisors' Opinion:

• [By John Udovich]

  Small cap security and surveillance stocks OSI Systems, Inc (NASDAQ: OSIS), Vimicro International Corporation (NASDAQ: VIMC), Analogic Corporation (NASDAQ: ALOG), Lifelock Inc (NYSE: LOCK) and View Systems Inc (OTCBB: VSYM) have been producing a steady flow of news lately that investors might want to take a closer look at. After all, the whole security and surveillance industry is pretty vast as it would include everything from airport scanners to security cameras to software securing everyone�� personal or online data. With that in mind, here is a look at the latest news from important small cap security and surveillance stocks:

• [By James E. Brumley]

  It's worth noting that it's not their fault. The measures needed to defend a primary and secondary school are foreboding, and can be expensive, and therefore are politically unpopular. Sadly though, each school shooting victim's death chips away at the disdain for physical barriers and checkpoints at a school's doors. Enter View Systems Inc. (OTCBB:VSYM).

5 Best Quality Stocks To Own For 2014: Redrow PLC (RDW)

Redrow PLC is a United Kingdom-based company engaged in residential development, which includes mixed use development. The Company�� operations are primarily focused on house building. Its completed projects include Signature, In the City/Regeneration and Debut. The Company's land holdings consist of both a current and forward land bank. As of June 30, 2010, the current land bank consisted of 11,600 plots owned with planning and 1,570 contracted plots, and its forward lank bank stood at around 22,000 plots. Its subsidiaries include Redrow Homes (Scotland) Ltd, Redrow Homes (Yorkshire) Ltd, Redrow Homes (Lancashire) Ltd, Redrow plc & Redrow Homes (NW) Ltd, Redrow Homes (Midlands) Ltd, Redrow Homes (South Midlands) Ltd, Redrow Homes (South West) Ltd, Redrow Homes (South Wales) Ltd and Redrow Homes (Eastern) Ltd. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Redrow Plc (RDW) rallied 3.2 percent to 245.6 pence as Deutsche Bank AG increased its 12-month share-price estimate and profit forecasts for 2013 and 2014. The U.K. builder yesterday jumped the most in five months after saying pretax profit for the year ended June will beat analysts��estimates.

5 Best Quality Stocks To Own For 2014: Veolia Environnement(VE)

Veolia Environnement S.A., together with its subsidiaries, provides environmental management services to individuals, public authorities, and industrial and commercial services customers worldwide. It operates in four segments: Water, Environmental Services, Energy Services, and Transportation. The Water segment offers water and wastewater services, including the management and operation of large-scale and customized drinking water plants, wastewater decontamination and recycling plants, drinking water distribution networks, and wastewater collection networks; and provision of call centers and billing services. The Environmental Services segment provides waste management and logistical services, which include waste collection, waste processing, cleaning of public spaces, maintenance of production equipment, treatment of polluted soil, and management of waste discharge at industrial sites. The Energy Services segment offers a range of energy management services comprising o peration of heating and cooling networks, decentralized energy production, thermal and multi-technical services, industrial utilities, installation and maintenance of production equipment, integrated facilities management, and electrical services on public streets and roads; and provides heating systems maintenance services, plumbing and renewable energy services, and meter-reading services. The Transportation segment operates various bus networks, suburban trains, tramways, metros, and ferries, as well as offers customized transportation-on-demand services. This segment also provides intercity and regional passenger transportation, infrastructure management and airport services, and transportation management services. The company was formerly known as Vivendi Environnement and changed its name to Veolia Environnement S.A. in April 2003. Veolia Environnement S.A. was founded in 1853 and is headquartered in Paris, France.

Advisors' Opinion:

• [By Sean Williams]

  Another factor that easily puts Waste Management on top in the waste-collection sector is its dividend yield of 3.4%. The only company with a higher yield is global waste solutions company Veolia Environnement (NYSE: VE  ) , with a 6.2% yield. However, Veolia also boats a higher debt-to-equity ratio than Waste Management, has unwanted exposure to European markets, and has lower overall margins relative to Waste Management. By comparison, Republic Services, Progressive Waste, and Waste Connections pay out a yield of 2.7%, 2.4% and 1%, respectively. Even better, Waste Management's payout has grown by an average annualized rate of 7.7% since 2004.

• [By Benjamin Shepherd]

  The first is to focus on infrastructure companies that lay the groundwork for easier water access, such as France-based Veolia Environment (NYSE: VE).

5 Best Quality Stocks To Own For 2014: Glu Mobile Inc.(GLUU)

Glu Mobile Inc. designs, markets, and sells mobile games worldwide. It develops original games based on its intellectual property comprising Big Time Gangsta?, Blood & Glory, Bug Village, Contract Killer, Contract Killer: Zombies, Eternity Warriors, Frontline Commando, Gun Bros, Men vs. Machines, Stardom: The A-List, Super K.O. Boxing and Toyshop Adventures. The company also develops games based on licensed intellectual property consisting of Build-a-lot, Call of Duty, Deer Hunter, DJ Hero, Guitar Hero, Family Feud, Family Guy, Lord of the Rings, Paperboy, The Price Is Right, Transformers, Who Wants to Be a Millionaire?, and World Series of Poker. It offers a portfolio of action/adventure and casual games to smartphones and tablet devices users through direct-to-consumer digital storefronts, as well as to feature phone users served by wireless carriers and other distributors. The company was formerly known as Sorrent, Inc. and changed its name to Glu Mobile Inc. in May 20 05. Glu Mobile Inc. was incorporated in 2001 and is headquartered in San Francisco, California.

Advisors' Opinion:

• [By Rick Munarriz]

  The market seems to think so. Shares of Zynga soared 23% last week on Mattrick's move. Even Glu Mobile (NASDAQ: GLUU  ) -- another publicly traded mobile gaming player -- popped 15% higher on the week.

• [By Jon C. Ogg]

  Glu Mobile Inc. (NASDAQ: GLUU) looked good and above estimates on the surface for its most recent quarterly earnings, but unfortunately it lowered sales estimates and expects a loss in the coming quarter. Glu shares are down 8.7% at $2.52 on Wednesday.

• [By vinaysingh]

  Mobile gaming is a hit-or-miss business and the past has shown that a few consecutive misses can push a company into a downward spiral. Glu Mobile (GLUU) is a prime example of this. The inability to develop chart-topping games took its toll on Glu, but the company has maneuvered a sensational turnaround in the last few months. However, even after the recent uptick, Glu is still a great long-term buy candidate. Let�� take a look at catalysts which will drive Glu Mobile higher in the foreseeable future.

• [By FinanceGuru]

  The mobile gaming market is a hit-or-miss industry and this volatility has taken its toll on many game-developing companies over the past few years. Companies like Zynga (ZNGA) and Glu Mobile (GLUU) have fallen prey to this uncertainty due to their inability to consistently create attractive games. Consequently, stocks of both companies have consistently tumbled since they went public.

Top Oil Service Companies To Invest In Right Now

Popular Posts: 5 Oil Services Stocks to Play Rising SpendingBe Wary of These 3 New MLP ETFs3 Healthcare Stocks for Retirement Investors Recent Posts: Now Is the Perfect Time to Buy Refining Stocks Is the Sun Fading on ETFs? – Morning Linkfest (July 7) Happy Birthday, ��urica … And New Stocks – Morning Linkfest (July 3) View All Posts Now Is the Perfect Time to Buy Refining Stocks

Sometimes, markets overreact to news.

5 Best Diversified Bank Stocks To Watch For 2015: YPF Sociedad Anonima(YPF)

YPF SOCIEDAD ANONIMA, an energy company, engages in the exploration, development, and production of crude oil, natural gas, and liquefied petroleum gas (LPG) in Argentina. The company also involves in refining, marketing, transportation, and distribution of oil and a range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels; and gas separation and natural gas distribution operations. As of December 31, 2010, it had proved reserves of approximately 531 million barrels of oil and 2,533 billion cubic feet of gas; and retail distribution network of 1,622 YPF-branded service stations for automotive petroleum products. The company?s crude oil transportation network includes approximately 2,700 kilometers of crude oil pipelines with approximately 640,000 barrels of aggregate daily transportation capacity of refined products; crude oil tankage of approximately 7 million barrels; and terminal facilities at 5 Argentine ports. In addition, it participates in 3 power stations with an aggregate installed capacity of 1,622 megawatts. The company was founded in 1977 and is based in Buenos Aires, Argentina. YPF SOCIEDAD ANONIMA is a subsidiary of Repsol YPF, S.A.

Advisors' Opinion:

• [By Garrett Cook]

  Energy shares dropped around 0.22 percent in today’s trading. Top decliners in the sector included Daqo New Energy (NYSE: DQ), PDC Energy (NASDAQ: PDCE), and YPF SA (NYSE: YPF).

Top Oil Service Companies To Invest In Right Now: Goldsearch Ltd (GSE)

Goldsearch Limited (Goldsearch) is an Australia-based minerals company. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in the exploration of gold and other minerals and investment activities. It operates in five segments: Mineral Exploration Sweden, Minerals Exploration Australia-Victoria, Minerals Exploration Australia-Other, Investments and Administration. Its other projects include the Mary Kathleen joint venture in Queensland and the Musgrave joint venture in South Australia. It held 16,000 square kilometres of tenements within the Musgrave Ranges of northwestern South Australia that were in joint venture between Goldsearch and Independence Group. During fiscal 2012, the Company held investments in Morning Star Gold NL (MCO) and Musgrave Minerals Ltd (MGV). On June 30, 2012, the Company had sold off its total investment in Independence Group NL (IGO). Its subsidiaries include: Caytale Pty Limited, Chiljill Pty Limited and Miltonpak Pty Limited. Advisors' Opinion:

• [By Roberto Pedone]

  Another environmental services player that looks ready to trigger a near-term breakout trade is GSE Holdings (GSE), which provides geosynthetic containment solutions for environmental protection and confinement applications. This stock has been hammered by the bears so far in 2013, with shares down big by 55%.

  If you take a look at the chart for GSE Holdings, you'll notice that this stock recently ripped sharply higher back above its 50-day moving average of $2.32 a share with heavy upside volume. Following that move, shares of GSE have started to trend sideways between $2.60 on the downside and $2.95 on the upside. Shares of GSE are now starting to move within range of triggering a near-term breakout trade above the upper-end of its recent range.

  Traders should now look for long-biased trades in GSE if it manages to break out above some near-term overhead resistance levels at $2.79 to $2.95 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 221,545 shares. If that breakout hits soon, then GSE will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.

  Traders can look to buy GSE off any weakness to anticipate that breakout and simply use a stop that sits right below support at $2.60 or below its 50-day moving average at $2.32 a share. One could also buy GSE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Oil Service Companies To Invest In Right Now: United Therapeutics Corporation(UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and internationally. It offers Remodulin, Tyvaso, and Adcirca for the treatment of pulmonary arterial hypertension (PAH). The company also develops Oral Treprostinil (UT-15C), a new drug application filed with the United States Food and Drug Administration for the treatment of PAH. Its development products under Phase III clinical trials include Oral Treprostinil (UT-15C) Combination Therapy for PAH; Ch14.18 monoclonal antibody (MAb) targeting Neuroblastoma; and Remodulin for the treatment of PAH in the United States, the United Kingdom, France, Germany, Italy, and Japan. The company?s development products under Phase I clinical trials comprise Beraprost-MR for PAH in North America, Europe, Mexico, South America, Egypt, India, South Africa, and Australia; 8H9 MAb targ eting Metastatic brain cancer; and IW001 for the treatment of Idiopathic pulmonary fibrosis and primary graft dysfunction. Its pre-clinical stage products consist of Glycobiology Antiviral Agents for viral infectious diseases; PLacental eXpanded cells targeting PAH; and pulmonary tissue replacement and remodeling products for the treatment of end-stage lung disease. The company serves pharmaceutical wholesalers through specialty pharmaceutical distributors and other distributors. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Advisors' Opinion:

• [By Ben Levisohn]

  United Therapeutics (UTHR) has zoomed to a 52-week high after a patent court gave it a partial victory in a lawsuit involving one of its drugs. ISI Group’s Mark Schoenebaum explains:

  Agence France-Presse/Getty Images

  The court ruling for the�United Therapeutics / Sandoz case was just posted. The judge ruled in favor of�United Therapeutics on the 2017 patent and in favor of Sandoz on the 2029 patent (United Therapeutics patent valid but Sandoz does not infringe) giving�United Therapeutics likely an additional 3 years protection on Remodulin.

  Investors were skeptical of a win on the 2017 patent (and gave very little credit to the 2029 patent given it was only on the diluent and Sandoz could have possibly just gotten a carve-out on the label). So this is close to a best case scenario in our view as the big overhang on�United Therapeutics appears to now be behind them and investors can consider owning�United Therapeutics for the potential for better than expected oral Orenitram sales.

  An additional 3 years of Remodulin protection adds ~$10 to our DCF.

  Leerink’s Joseph Schwartz and Paul Matteis doesn’t think the news is as good as the market thinks it is:

  While the order is likely to lead to a modest raise of near term consensus estimates, we believe that the decision re-affirms our long-term cautious view on�United Therapeutics shares given the 1) near certainty now that Remodulin will go generic in 2H17 and 2) greater need for�United Therapeutics to create value through creatively deploying its free cash flow, which in recent history has mostly been used to fund operations and buy back stock. Thus, while the ruling today likely solifidies United Therapeutics’ 2015-2016 earnings potential, based on our sensitivity analysis we believe that the near certain presence of a generic in 2017 implies significant downside to the NPV of the remodulin franchise, contrary to the positive stock reaction to the

• [By Jim Fink]

  United Therapeutics (NASDAQ: UTHR) is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.�The stock jumped to a 52-week high after a federal court gave it a partial victory in a patent lawsuit involving one of its drugs.

• [By Myra Ramdenbourg]

  United Therapeutics Corp (UTHR): John Maxim Ferrari sold 10,000 Shares

  On 10/02/2014, CFO John Maxim Ferrari sold 10,000 shares at an average price of $129.46. The price of the stock has decreased by 2.69% since. United Therapeutics Corp has a market cap of $5.95 billion and its shares were traded at around $125.98. The company has a P/E ratio of 24.70 and P/S ratio of 5.72. Over the past 5 years, United Therapeutics Corp had an annual average earnings growth of 68.10%.

Top Oil Service Companies To Invest In Right Now: Calwest Bancorp (CALW)

CalWest Bancorp owns South County Bank, National Association. The Company is the holding company for South County Bank N.A. South County Bank operates in four divisions: business solutions, professional division, personal services and online banking. Business solutions are engaged in deposit services, cash management solutions and loan services. Professional division is engaged in physicians, dentists, veterinarians, attorneys and certified public accountants. Personal services include deposit services and loan services. Online banking includes personal login, cash management login, cash management demos and user resources.

Business solutions

Deposit services include analysis checking, unlimited checking, interest checking, money market savings, sweep accounts, zero balance accounting, payroll services and merchant card processing. Cash management services include eCorp online banking, remote deposit, electronic payments, positive pay, mobile banking, cash vault and armored transport. Its loan services include business lines of credit, commercial term loans, commercial real estate loans, equipment loans, SBA financing, construction loans and accounts receivable financing.

Professional division

Veterinarians provide deposit services, cash management services and lending services. Attorneys and certified public accountants also include deposit services, cash management services and lending services

Personal services

Deposit services include online banking, checking, saving, money market, certified deposit and retirement accounts. Its loan services include overdraft protection, home equity lines and vehicle financing.

Advisors' Opinion:

• [By CRWE]

  Today, CALW remains (0.00%) +0.000 at $.370 thus far (ref. google finance 10:58AM EDT July 24, 2013).

  CalWest Bancorp previously reported the consolidated financial results for the six months ended June 30, 2013. Significant items for the period ending June 30, 2013 include:

  Quarterly net income of $50,000, compared to the previous quarter profit of $12,000;
  No additional loan loss provision required; resulting in the allowance for loan loss (ALL) ratio decreasing slightly from 6.20% to 5.95%;
  Total assets were flat at $144 million, with new business offsetting run-off;
  Non-performing loans reduced significantly in 2013 by 41% quarter-over-quarter; and are down $1.9 million from a year ago;
  Non-interest bearing deposits maintained at 35% of total deposits, helping reduce the Bank�� cost-of-deposits to 0.40% from 0.48% a year ago;
  The increase in Net Interest Income offset the reduction in Non-Interest Income as increased focus is placed on core earnings;
  Non-interest expenses continue to improve, decreasing 2% quarter-over-quartee

Top Oil Service Companies To Invest In Right Now: Humana Inc.(HUM)

Humana Inc. offers various health and supplemental benefit plans in the United States. Its Government segment consists of beneficiaries of government benefit programs; and operates in three lines of businesses, including Medicare, Military, and Medicaid. The Medicare program provides hospital and medical insurance benefits to persons of age 65 and over and some disabled persons under the age of 65. The Military program offers health insurance coverage to the dependents of duty military personnel, and to retired military personnel and their dependents. The Medicaid program is a federal program that is state-operated to facilitate the delivery of health care services primarily to low-income residents. The Commercial segment consists of members enrolled in its medical and specialty products marketed to employer groups and individuals. This segment provides health maintenance organization products that offer prepaid health insurance coverage to its members through a network of independent primary care physicians, specialty physicians, and other health care providers; preferred provider organization products, which are offered primarily to employer groups and individuals; and administrative services only products that are provided to employers who self-insure their employee health plans. It also offers various specialty products, including dental, vision, and other supplemental products, as well as disease management services. As of December 31, 2010, Humana Inc. had approximately 10.2 million members enrolled in medical benefit plans; and approximately 7.1 million members enrolled in specialty products programs. The company markets its products through various channels comprising television, radio, the Internet, telemarketing, and direct mailings. In addition, it has strategic alliances with Wal-Mart Stores, Inc.; State Farm; and United Services Automobile Association to market its products. The company was founded in 1961 and is headquartered in Louisville, Kentucky.

Advisors' Opinion:

• [By Ben Levisohn]

  Earlier today, the S&P 500 looked like it would close at an all-time high. Then the bears roared, and S&P 500 gave back about half its gains despite big moves in United Health (UNH), Humana (HUM), Pioneer Natural Resources (PXD),�ExxonMobil (XOM) and� Regeneron (REGN).

• [By Sara Ashley O'Brien]

  The Bluegrass State's largest city has also had a big impact on small business optimism. Louisville is home to the headquarters of Humana (HUM), the U.S. headquarters of Yum! Brands (YUM) and UPS' (UPS) worldwide air hub. But the city is a great place for small businesses too, as evidenced by its rank in the Thumbtack survey: number 5 out of 82.

• [By Keith Speights]

  Anthem, which is owned by WellPoint (NYSE: WLP  ) , for example, required prior authorizations only 2.14% of the time. Cigna (NYSE: CI  ) and Aetna (NYSE: AET  ) have higher frequencies -- 4.74% and 5.42%, respectively. Humana (NYSE: HUM  ) is even higher, but still in the single digits with a 8.42% prior authorization rate. Of the publicly traded insurers, only UnitedHealth Group (NYSE: UNH  ) requires prior authorizations more than 10% of the time, with a rate of 12.43%.

Top Oil Service Companies To Invest In Right Now: Flamel Technologies S.A.(FLML)

Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer based technology in the United Kingdom, Ireland, the United States, France, and Europe. The company develops nanogel Medusa technology, which is intended to provide controlled release following injection of therapeutic proteins, peptides, and other molecules; a microparticle adaptation of the Medusa platform that is intended for use in the delivery of smaller proteins and peptides; and Micropump technology, a microparticle technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology, an adaptation based on Micropump technology, which is intended to minimize the misuse and abuse of medications subject to abuse. Its principal product based on Micropump technology is Coreg CR, which is intended for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. The company?s products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus and as a immune response; and FT-105, an injectable insulin formulation for diabetic patients. Its products based on its Micropump technology comprise LiquiTime for the elderly and pediatric patient patients, or others who have difficulty swallowing. The company has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; and Pfizer Inc, as well as has a joint development agreement with Digna Biotech, S.L. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France.

Advisors' Opinion:

• [By Anna Prior]

  Flamel Technologies SA(FLML) said the U.S. Food and Drug Administration has approved the company’s new drug application for Vazculep, an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. American depositary shares rose 5.1% to $14.78 in premarket trading.

• [By Garrett Cook]

  Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).

Top Oil Service Companies To Invest In Right Now: Liquidmetal Technologies Inc (LQMT)

Liquidmetal Technologies, Inc. (Liquidmetal Technologies), incorporated in 1987, is materials technology company that develops and commercializes products made from amorphous alloys. The Company's Liquidmetal family of alloys consists of a variety of bulk alloys and composites that utilize the advantages offered by amorphous alloy technology. The Company designs develop and sell products and components from bulk amorphous alloys to customers in various industries. The Company also partners with third-party manufacturers and licensees to develop and commercialize Liquidmetal alloy products. The Company focused to commercializes its Liquidmetal alloys on three identified product areas, such as Components for Non-Consumer Electronic Products, Sporting Goods and Leisure Products and Medical Devices. On December 1, 2011, the Company entered into a Share Purchase Agreement with LMTK Holdings, Inc. (LMTK Holdings) to sell its former Korean subsidiary and manufacturing facility, Liquidmetal Technologies Korea (LMTK). Under the Share Purchase Agreement, the Company sold all of LMTK�� shares of common stock to LMTK Holdings.

The Company designs, develops and produces components for non-consumer electronic devices utilizing its bulk Liquidmetal alloys. The product categories in the non-consumer electronics field include, but are not limited to, parts for high end printers, commercial imaging devices, aerospace components, medical devices and industrial machines. The Company is also developing a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area.

The Company develops a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area. In the sporting goods industry the Company focuses on products that meet its design criteria. The Company has produced prototype rings made from an amorphous Liquidmetal platinum alloy that is harder, in the leisure products category. The Company emphasis on surgical instrument appl! ications for Liquidmetal alloys. These include, but are not limited to, specialized blades, orthopedic instruments utilized for implant surgery procedures, dental devices and general surgery devices

The Company is engaged in product development efforts relating to various medical devices that could be made from bulk Liquidmetal alloys. The properties of bulk Liquidmetal alloys provide a combination of performance that makes them a replacement to incumbent materials, such as stainless steel and titanium.

Advisors' Opinion:

• [By James E. Brumley]

  Looking for a couple of near-term trades that have a decent shot at rallying even if the broad market feels like it might pull back? Then take a look at Liquidmetal Technologies Inc. (OTCBB:LQMT) and NanoTech Entertainment, Inc. (OTCMKTS:NTEK). Although both LQMT and NTEK will be dismissed by some traders simply because they're OTC-listed stocks, for those traders willing to look past the exchange and appreciate the opportunity, the risk-versus-reward ratio is actually quite compelling.

• [By James E. Brumley]

  While it may be melodramatic to say my following of Liquidmetal Technologies Inc. (OTCBB:LQMT) has been something of a 'saga', it wouldn't be unfair to say it's one of those small cap stocks that's had its fair share of twists and turns. Yours truly turned explicitly bullish on LQMT back on November 22nd, after the stock broke above a key falling resistance lines. Then, on January 14th, I made a point of saying the rally had run its course, and it was time to lock in your 47% gain on Liquidmetal Technologies and walk away... at least for a while.

• [By James E. Brumley]

  The 7% pop we're seeing from Liquidmetal Technologies Inc. (OTCBB:LQMT) today is impressive, but we've all seen big - and even bigger - gains from stocks before. What makes this one any different than the hundred of other stocks that dole out one-day wonder gains on any given trading day? Well, as it turns out, there actually is something significantly different with the way LQMT is flying high today.

• [By Bryan Murphy]

  With just a quick glance at its chart, Liquidmetal Technologies Inc. (OTCBB:LQMT) looks like little more than a tangled, indecisive mess. As you take a longer look at LQMT chart though, a modest bullish hint starts to appear. This may be one of the budding superstar stocks for Q4.

Best Industrial Disributor Companies To Watch For 2015

Best Industrial Disributor Companies To Watch For 2015: Enzo Biochem Inc. (ENZ)

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molec ules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Advisors' Opinion:

• [By CRWE]

  Enzo Biochem Inc. (NYSE:ENZ) is a pionee! r in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-industrial-disributor-companies-to-watch-for-2015.html

Hot European Stocks To Own Right Now

This crowded trade statement currently is apropos in regards to US and European equities, writes MoneyShow's Jim Jubak, also of Jubak's Picks, however, that does not mean these stocks have to decline.

It's one concept that my friend, Peter Tchir, of TF Market Advisors, uses to assess the potential risk and reward of a strategy. In concept, it's pretty simple: Look to see how much of the market, how much of the available money, is already lined up on one end of a trade or the other. And ask, how much more money is available to further push up an already popular trade, or what it would take to get money to flow into the currently unpopular end of a trade. (The concept is simple. Where Peter and his partner Jeremy Hill excel is in figuring out how to measure how crowded a trade might be.)

Looking at the markets right now, I'd have to say, being long US equities is a very crowded trade.

As of September 27, Markit Securities reports that only 2.4% of the shares in the companies on the Standard & Poor's 500 are out on loan to short sellers. That's near a record low.

Best Telecom Companies To Invest In Right Now: BP p.l.c.(BP)

BP p.l.c. provides fuel for transportation, energy for heat and light, retail services, and petrochemicals products. Its Exploration and Production segment engages in the oil and natural gas exploration, field development, and production; midstream transportation, and storage and processing; and marketing and trading of natural gas, including liquefied natural gas (LNG), and power and natural gas liquids (NGL). This segment has exploration and production activities in Angola, Azerbaijan, Canada, Egypt, Norway, Russia, Trinidad and Tobago, the United Kingdom, and the United States, as well as in Asia, Australasia, South America, North Africa, and the Middle East. This segment also owns and manages crude oil and natural gas pipelines; processing facilities and export terminals; and LNG processing and transportation, as well as NGL extraction facilities. BP p.l.c. has interests in the Trans-Alaska pipeline system, the Forties pipeline system, the Central Area transmission sys tem pipeline, the South Caucasus Pipeline, and Baku-Tbilisi-Ceyhan pipeline, as well as in LNG plants located in Trinidad, Indonesia, and Australia. The company?s Refining and Marketing segment involves in the supply and trading, refining, manufacturing, marketing, and transportation of crude oil, petroleum, and petrochemicals products and related services to wholesale and retail customers primarily under the BP, Castrol, ARCO, and Aral brands. Its Other Businesses and Corporate segment produces and markets rolled aluminum products, as well as generates energy through wind, solar, biofuels, hydrogen, and carbon capture and storage sources; and engages in shipping activities. The company was founded in 1889 and is headquartered in London, the United Kingdom.

Advisors' Opinion:

• [By Fede Zaldua]

  I have been buying British Petroleum's (BP) shares for over a year but the stock, which is now up by 10.2% year to date, largely underperformed the S&P 500 index and most of its peers in the oil & gas industry. That said, the market sentiment seems to be finally turning thanks to better than expected results and management's promise of giving back more cash to shareholders. Let's take a look at this quarter�� results and let's try to make an educated guess on what might be coming up in the future.

• [By Claudia Assis]

  Energy companies in the Gulf also shut down about 40% of natural gas production. Several energy firms, including BP PLC (BP) , Anadarko Petroleum Corp. (APC) , Royal Dutch Shell PLC (RDS.A) ,�Exxon Mobil Corp. (XOM) �and Chevron Corp. (CVX) , began evacuating workers earlier in the week.

• [By Arjun Sreekumar]

  But according to a recent report by BP (NYSE: BP  ) , the global LNG trade experienced its first ever annual decline last year. Let's take a closer look at why it fell and what the future may hold.

Hot European Stocks To Own Right Now: STMicroelectronics N.V.(STM)

STMicroelectronics N.V., an independent semiconductor company, engages in the design, development, manufacture, and marketing of a range of semiconductor integrated circuits and discrete devices. Its products include discrete and standard commodity components, application-specific integrated circuits, custom devices and semi-custom devices, and application-specific standard products for analog, digital, and mixed-signal applications. The company also offers subsystems and modules for the telecommunications, automotive, and industrial markets comprising mobile phone accessories, battery chargers, ISDN power supplies, and in-vehicle equipment for electronic toll payment, as well as provides Smartcard products. Its products are used in various microelectronic applications consisting of automotive products, computer peripherals, telecommunications systems, consumer products, industrial automation, and control systems. The company sells its products through distributors and ret ailers. STMicroelectronics N.V. was founded in 1987 and is headquartered in Geneva, Switzerland.

Advisors' Opinion:

• [By Vanina Egea]

  Reed Elsevier NV (ENL) is a diversified publisher and information provider. It works on a wide range of market segments that include scientific, technical and medical (STM); legal; risks solutions and business information and exhibitions. The key of the company�� growth, however, lies almost exclusively in two brands: Elsevier and LexisNexis.

Hot European Stocks To Own Right Now: Aegon NV(AEG)

AEGON N.V. provides life insurance, pensions, and asset management products and services worldwide. The company?s life insurance products include traditional, term, universal, whole, and other life insurance products sold as part of defined benefit pension plans, endowment policies, post-retirement annuity products, and group risk products; supplemental health insurance products comprise accidental death, other injury, critical illness, hospital indemnity, medicare supplement, and student health; specialty lines consists of travel, membership, and creditor products; and long term care insurance products for policyholders who require care due to a chronic illness or cognitive impairment. It also offers a range of savings and retirement products and services, including mutual funds, and fixed and variable annuities, savings accounts and investment contracts, segregated funds, guaranteed investment accounts, and single premium immediate annuities, as well as investment advice to individuals. In addition, the company offers employer solutions and pensions, such as retirement plans, pension plans, and pension-related products and services; investment products, including onshore and offshore bonds, and trusts; reinsurance products and solutions to life insurance and financial services companies; general insurance products comprising house, car, and fire insurance; and asset management products and services, including general account assets, unit-linked funds, and third party activities. AEGON N.V. markets its products through independent and career agents, financial planners, registered representatives, independent marketing organizations, banks, broker-dealers, benefit consulting firms, wirehouses, affinity groups, institutional partners, independent managing general agencies, and specialized financial advisors, as well as through online, direct, and worksite marketing. The company was founded in 1900 and is headquartered in The Hague, the Netherl ands.

Advisors' Opinion:

• [By Will Ashworth]

  Assuming it delivers on its outlook for 2014, its current free cash flow yield is a very enticing 20%. This isn�� a growth stock, but its brands still possess hidden value. As cheap stocks go, it�� very attractive.

  Cheap Stocks to Buy: Aegon (AEG)

  It�� not often that you can buy a $19 billion market cap for under 10 bucks. Aegon�� a Dutch insurance company that�� had a rough ride over the past few years, and its stock�� suffered as a result. In the late ’90s AEG stock traded around $60 — it hasn�� been anywhere close since. However, it�� got some good assets that should bear fruit in the years to come. Aegon has 12,000 employees in the Americas doing business primarily under the Transamerica brand, which has been a part of AEG since 1999.

Hot European Stocks To Own Right Now: Telefonica SA(TEF)

Telefonica, S.A. provides fixed and mobile telephony services primarily in Spain, rest of Europe, and Latin America. Its fixed telecommunication services include PSTN lines; ISDN accesses; public telephone; local, domestic, and international long distance and fixed-to-mobile communications; corporate communications; video telephony; supplementary and business-oriented value-added services; network services; leasing and sale of handset equipment; and telephony information services. The company?s Internet and broadband multimedia services comprise Internet service provider service; portal and network services; retail and wholesale broadband access; narrowband switched access to Internet; naked ADSL, a broadband connection; residential-oriented value-added services; companies-oriented value-added services; television services, such as IPTV, cable television, and satellite television; and Fiber to the Home, a service for high speed Internet access and digital video recording. Its data and business-solutions services principally include leased lines; virtual private network services; fiber optics services; the provision of hosting and application; outsourcing and consultancy services; desktop services; and system integration and professional services. The company?s wholesale services for telecommunication operators primarily comprise domestic interconnection services; international wholesale services; leased lines for other operators? network deployment; local loop leasing under the unbundled local loop regulation framework; and bit stream services. It also offers various mobile and related services and products that include mobile voice services, value added services, mobile data and Internet services, wholesale services, corporate services, roaming, fixed wireless, and trunking and paging services. The company has a strategic alliance with China Unicom (Hong Kong) Limited. Telefonica, S.A. was founded in 1924 and is headquartered in Madrid, Spai n.

Advisors' Opinion:

• [By Amy Thomson]

  AT&T has examined takeover candidates including Vodafone�� assets, U.K. mobile carrier EE -- a venture of Deutsche Telekom AG (DTE) and Orange SA (ORA) -- and parts of Spain�� Telefonica SA (TEF), people familiar with the company�� plans said in June. AT&T is attracted to Europe because of its relatively recent introduction of faster, fourth-generation networks, which have been available for years in the U.S.

• [By The Investment Doctor]

  In this article I'll follow up on my earlier article on Telefonica (TEF) 'Why Telefonica might be a good investment right now', and have a look at the company's H1 financial results which were published last week. I'll first discuss the numbers, have a closer look at the debt level (as it's one of Telefonica's priorities to considerably reduce this debt) and give my updated opinion at the end of this article.

• [By Charles Sizemore]

  Next Page

  European Dividend Stocks to Buy: Telefonica (TEF)

  Dividend Yield: 6%

  And finally, we get to one of my favorite long-term holdings, Spanish telecom giant Telefonica (TEF).

• [By Charles Sizemore]

  So, what does this mean for AMX stock and for its largest single competitor in Latin America, Spain��Telefonica (TEF)?

  To start, this will, by default, massively diversify AMX�� revenue stream globally. Though AMX is the number-one or number-two mobile provider in nearly every Latin American country, its home market of Mexico is by far its biggest. Mexico currently accounts for about a third of sales and nearly half of profits. The new AMX will be a pan-Latin-American telecom giant based in Mexico rather than a Mexican telecom giant with operations in Central and South America.

10 Best Medical Stocks To Watch For 2015

Normal neural activity results from a balance of electrical and chemical signals that are vulnerable to disruption by trauma to the nervous system.�Similar to the way a cardiac pacemaker corrects heartbeat abnormalities, neuromodulation therapies help to re-establish normal neural function by�allowing focused delivery of therapeutic agents to precisely targeted areas of the nervous system.�

The most common neuromodulation therapy is spinal cord stimulation.�California's privately owned Spinal Modulation has developed a new pain management option for patients with chronic, intractable pain -- the Axium Neurostimulator System, which targets the dorsal root ganglion of the spinal cord and consists of a specialized lead, delivery platform, and electrical stimulator.

St. Jude Medical (NYSE: STJ  ) �announced�Friday that it has entered into a series of agreements whereby St. Jude will invest $40 million in SM. The agreement provides St. Jude with an exclusive option to distribute the Axium Neurostimulator in international markets in which it is approved for sale. St. Jude will also have the exclusive option to acquire all of SM for up to $300 million, plus payment of certain revenue-based milestones, following U.S. commercialization of the product.�

10 Best Medical Stocks To Watch For 2015: Bio-Reference Laboratories Inc.(BRLI)

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

Advisors' Opinion:

• [By Geoff Gannon] strong>DreamWorks (DWA)

  Read these reports. Look for something that might have interested me. Why would Geoff look at DNB, Chuck E. Cheese, etc.? What got him interested in the stock? Do I see the same thing?

  Whenever possible, also read the quarterly earnings call transcripts. You can listen to them too. But it�� easier if you read them and listen to them.

  Just listening is a bad idea.

  Whenever I can get a transcript of anything ��even Warren Buffett�� appearance on CNBC ��I��l keep a copy of the transcript even when I have a copy of the video (or audio). You can refer back to a transcript easily. You can highlight. You can take notes.

  Taking Notes

  Now, you are doing those things when reading an annual report, right?

  You never just sit down and read an annual report. You always sit down with a pen, a highlighter, a pad of paper, and a calculator. Use the margins of a 10-K ��or your pad of paper ��to jot down notes. Ask questions. Do calculations.

  If you ever see a 10-K after I��e read it ��it�� not very white anymore. There�� lots of stuff written in the margins. Mostly it�� questions I was asking myself. But it�� also calculations of numbers the company does not provide.

  Numbers to Know

  So, for example, in a bank�� 10-K I always write down:

  路 Deposits per share

  路 Deposits per branch

  路 Cost of deposits

  路 Texas Ratio

  You can actually look up the Texas Ratio of any bank here. And some banks calculate and report cost of deposits the way I like to think about it. But, it�� not common for banks to report deposits per branch ��although small banks will sometimes mention (perhaps in the shareholder letter) what their biggest branch has in deposits. Others may mention how quickly new branches achieved a deposit milestone.

  Those are the kinds of numbers I write in the margins of a bank�� 10-K. There will be questions like: ��hy is e

• [By Ben Levisohn]

  As a result, LabCorp has dropped 11% to $87.79 and has helped drag down competitors like Quest Diagnostics (DGX), and BioReference Laboratories (BRLI).

10 Best Medical Stocks To Watch For 2015: Discount Dental Materials Inc (DDOO)

Discount Dental Materials, Inc. (DDM), incorporated on December 18, 2007, is a development-stage company. The Company focuses on selling disposable dental supply products at discount prices over the Internet. As of November 30, 2011, the Company had not generated any revenues.

The Company focuses on selling a limited number of products including burs (modern dental drills that can rotate at up to 800,000 revolutions per minute (rpm) and generally use hard metal rotary files). Dental burs come in a variety of shapes designed for specific applications. They are often made of steel with a tungsten carbide coating or of tungsten carbide entirely. The bur may also have a diamond coating), bearings, turbines and sterilization pouches. The Company uses a facility in Burbank, California to store and ship products.

The Company competes with Henry Schein and Patterson Dental.

Advisors' Opinion:

• [By CRWE]

  Last Friday, DDOO previously surged (+5.00%) up +0.05 at $1.05 with 10,200 shares in play at the close (ref. google finance June 28, 2013 ��Close).

  Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

  Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

• [By CRWE]

  Today, DDOO remains (0.00%) +0.000 at $1.05 thus far (ref. google finance Delayed:� 3:42PM EDT July 1, 2013).

  Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. , previously reported that medical device product development company, Sonos Models, Inc. (��onos��, is set to complete the first prototypes of its medical device solution during the company�� first fiscal quarter, which begins July 1, 2013.

  Cerebain�� President, Eric Clemons, stated, ��e are excited with the imminent completion of the first set of prototypes of our Medical Device Product for the treatment of Alzheimer�� Disease. Years of hard work and research will culminate with the introduction of these prototypes which will utilize the Omentum for the treatment of patients with this debilitating disease. With these prototypes, we are introducing a leading edge approach to the treatment of Alzheimer�� Disease.��/p>

Best New Companies To Invest In Right Now: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:

• [By Brian Orelli]

  That seems to be what Johnson & Johnson (NYSE: JNJ  ) and Bristol-Myers Squibb (NYSE: BMY  ) are thinking with the clinical trial collaboration agreement they entered�to test Johnson & Johnson's Imbruvica with Bristol-Myers Squibb's Opdivo in multiple types of blood cancer.

10 Best Medical Stocks To Watch For 2015: Sirona Dental Systems Inc (SIRO)

Sirona Dental Systems, Inc. (Sirona), incorporated on April 25, 1997, and its subsidiaries is a manufacturer of dental equipment, and is focused on developing, manufacturing and marketing solutions for dentists around the world. The Company operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers and Instruments. The Company markets its products globally to dental practices, clinics and laboratories through an international network of distributors. The dental distributors supply both dental equipment and consumables, and have regular contact with the ultimate end-users. In addition, the Company also distributes its products through its own sales and services infrastructure.

Dental CAD / CAM Systems

Dental CAD/CAM Systems address the dental restorations, which includes several types of restorations, such as inlays, onlays, veneers, crowns, bridges, copings and bridge frameworks made from ceramic, metal or composite blocks. Sirona's CEramic REConstruction (CEREC) system is an in-office application that enables dentists to produce high quality restorations from ceramic material and insert them into the patient's mouth during a single appointment. The CEREC system consists of an imaging unit and a milling unit. The imaging unit scans the damaged area, captures the image of the tooth or teeth requiring restoration and proposes the specifications for the restoration. The milling unit then mills the ceramic restoration to the required specifications based upon the captured image and the dentist's design specifications.

Sirona offers a service contract on its CEREC product, which includes software updates and upgrades and maintenance on software-related hardware. In addition to CEREC, Sirona also offers CAD/CAM products for dental laboratories, including the inLab restoration fabrication system and the extra-oral inEos scanner. These products are designed to improve efficiency and reduce costs for the dental lab. The inLab system scans the ! models received from the dentists and then mills ceramic or composite block restorations, such as crown copings and bridge frameworks to the specifications of the captured image.

Imaging Systems

Imaging Systems comprise a broad range of systems for diagnostic imaging in the dental practice. Sirona has developed a comprehensive range of imaging systems for two dimensional (2D) or three dimensional (3D), panoramic and intra-oral applications. Intra-oral x-ray systems use image-capture sensor devices, which are inserted into the mouth behind the diagnostic area, and take images of one or two teeth. Panoramic x-ray systems produce images of the entire jaw structure by means of an x-ray tube and an image capture device, which rotates around the head.

Treatment Centers

Treatment Centers consists of a range of products from basic dentist chairs to chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, as well as specialist centers used in preventative treatment and for training purposes. Sirona offers specifically configured products to meet the preferences of dentists within each region in which it operates. Sirona's treatment center configurations and system integration are designed to enhance productivity by creating a seamless workflow within the dental practice.

Instruments

Sirona offers a range of instruments, including handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis, which are regularly updated and improved. The instruments are supplemented by multi-function tips, supply and suction hoses, as well as care and hygiene systems for instrument preparation. Sirona's instruments are often sold as packages in combination with treatment centers.

Advisors' Opinion:

• [By Ben Levisohn]

  Shares of Align have surged 24% to $57 at 12:37 p.m. Sirona Dental Systems (SIRO) has risen 0.8% to $69.61, Dentsply International (XRAY) is up 0.1% at $45.44, Integra Lifesciences (IART) has� gained 0.4% to $44.23 and Danaher (DHR) has fallen 0.3% to $72.13.

• [By Todd Campbell]

  Dentists may find that patients are more willing to spend on restorative procedures now that the job market is recovering and consumer sentiment is heading higher. That offers new opportunities for providers of dentistry equipment, such as Sirona Dental Systems (NASDAQ: SIRO  ) , a company that was spun out of Siemens in 1997 and brought public in 2006.

10 Best Medical Stocks To Watch For 2015: Senesco Technologies Inc (SNTI)

Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.

Human Therapeutic Applications

The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.

The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.

Agricultural Applications

The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.

The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.

Advisors' Opinion:

• [By CRWE]

  Today, SNTI has shed (-2.44%) down -0.0010 at $.0400 with�723,673 shares in play thus far (ref. google finance Delayed: 2:58PM EDT October 7, 2013).

  Senesco Technologies, Inc. previously reported it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.

  The offering is expected to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily for working capital, research and development and general corporate purposes.

10 Best Medical Stocks To Watch For 2015: Decision Diagnostics Corp (DECN)

Decision Diagnostics Corp., formerly instaCare Corp., incorporated on March 2, 2001, is a prescription and non-prescription diagnostics and home testing products distributor. The Company distributes brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound cares and post-surgery medical products. The Company through its subsidiaries, PDA Services, Inc. and Decision IT Corp. offers information technology solutions in several medical cares market channels by providing physicians with information at the point of care. The Company's retail prescription business maintains three operating units, which include Licensed wholesale prescription drug distribution business; Licensed distribution of diabetes diagnostics and supplies; and Internet pharmacy/prescription fulfillment.

The Company's software is designed to integrate point of service applications. The Company is also a developer of products that offer solutions in medical care and management by providing physicians with essential information instantaneously as they meet with their patients. In addition, the Company markets its MD@Hand and MD @Work software application, which also leverages the connectivity of smart cell phones devices through the Internet. The Company's applications run on smart phones manufactured by Apple, Palm, Motorola and Samsung.

Advisors' Opinion:

• [By Bryan Murphy]

  Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).

10 Best Medical Stocks To Watch For 2015: Medtronic Inc (MDT)

Medtronic, Inc. (Medtronic), incorporated on April 23, 1957, is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. In August 2013, Medtronic, Inc. announced the closing of the acquisition of Cardiocom. Effective September 3, 2013, Medtronic Inc acquired a 30% stake in NGC Medical SpA.

Cardiac Rhythm Disease Management

CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. The Company's principal products offered by CRDM business include Implantable Cardiac Pacemakers (Pacemakers), Implantable Cardioverter Defibrillators (ICDs), Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps), AF Products, Diagnostics and Monitoring Devices and Patient Management Tools. The Company's pacemaker systems are compatible with certain magnetic resonance imaging (MRI) machines. This includes the Revo MRI SureScan with United States Food and Drug Administration approval and the Advisa and Ensura MRI SureScan models with Conformite Europeene (CE)! Mark approval. Medtronic also continues to market the Adapta product family, which includes the Adapta, Versa, Sensia, and Relia models.

The Medtronic ICDs is the Protecta family with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures. Devices in the ICD family are the Protecta XT, Protecta, Cardia, and Egida models. Medtronic also continues to market the Secura and Maximo II devices. The Medtronic CRT-Ds is the Protecta family with SmartShock technology, including Protecta XT and Protecta, and the CRT-P devices are Consulta and Syncra. Medtronic also continues to market the Consulta, Cardia, Egida, and Maximo II CRT-D devices. In addition to these devices, Medtronic has an offering of left heart leads and delivery catheters with its Attain family of products. The Company's portfolio of AF products includes the Arctic Front Cardiac CryoAblation Catheter designed to treat paroxysmal AF by performing pulmonary vein isolation. The Company also offers the Reveal XT Insertable Cardiac Monitor, which is designed to identify and quantify episodes of AF. The Reveal DX and Reveal XT Insertable Cardiac Monitors devices are used to record the heart's electrical activity before, during, and after transient symptoms such as syncope and palpitations to help provide a diagnosis. It has a number of patient management tools, such as CareLink, Paceart, and CardioSight Service. CareLink enables patients to transmit data from their pacemaker, ICD, CRT-D, or Insertable Cardiac Monitors using a portable monitor that is connected to a standard telephone line or cellular network using the Medtronic M-Link accessory.

The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc. and Sorin Group.

CardioVascular

CardioVascular is comprised of three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. The Coronary business includes therapies to treat ! coronary ! artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, along with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories. The products offered by its Coronary business include Percutaneous Coronary Intervention (PCI) and Renal Denervation. The Endovascular and Peripheral business is comprised of a range of products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). The Company's products include endovascular stent graft systems, embolic protection systems, and stent systems for the treatment of narrowed iliac arteries. The products offered by the Company's Endovascular and Peripheral business include Endovascular Stent Grafts and Peripheral Vascular Intervention (PVI). The Structural Heart business offers a range of products and therapies to treat a variety of heart valve disorders. The Company's products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The Company's principal products offered by its Structural Heart business include Heart Valves, Transcatheter Heart Valves, Arrested Heart Surgery, Beating Heart Surgery and Surgical Ablation.

The Company competes with Abbott Laboratories, Boston Scientific, and Johnson & Johnson, Cook, Inc., W. L. Gore & Associates, Inc., Endologix, Inc., C.R. Bard, Inc., Edwards LifeSciences Corporation, St. Jude, Terumo Medical Corporation and Sorin Group.

Spinal

The Company's Spinal business develops, manufactures, and markets a range of medical devices and implants used in the treatment of the spine and musculoskeletal system. The Company's products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumours, fractures ! of the sp! ine, and stenosis. The Company's Spinal business also provides biologic solutions for the dental and orthopedic markets. The Company's Spinal products are used in spinal fusion of both the thoracolumbar region, referring to the mid to lower vertebrae, as well as of the cervical region, or upper spine and neck vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and interbody devices, as well as biologics products, primarily bone growth substitutes including bone graft extenders and structural allografts such as dowels and wedges. The products offered by the Company's Spinal business include Thoracolumbar Products, Cervical Products and Biologics Products.

The Company competes with DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. and Johnson & Johnson.

Neuromodulation

The Company's Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. The l products offered by the Company's Neuromodulation business includes Neurostimulators for Chronic Pain, Implantable Drug Delivery Systems, Deep Brain Stimulation (DBS) Systems and Urology, Fecal, & Gastroenterology Devices. The Company's portfolio of products includes the RestoreSensor (rechargeable), with the Company's AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.

DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. The Company's family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). The Company's therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients.

The Company's competes with Boston Scientific, St. Jude., Urologix, Inc. and Allergan.

Diabetes

The Company's Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The products offered by the Company's Diabetes business includes Integrated Diabetes Management Solutions, Professional CGM and CareLink Therapy Management Software. Outside the United States, the Company offers its Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the United States, the Company offers the Paradigm Revel System, which incorporates new CGM features, including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Medtronic offers physicians a Professional CGM product called the iPro CGM and iPro2 Professional CGM. The Company offers Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to helps patients and their health care prov! iders con! trol their diabetes.

The Company competes with DexCom, Inc., Insulet Corporation, Johnson & Johnson and Roche Ltd.

Surgical Technologies

The Company's Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The products offered by the Company's Surgical Technologies business includes ENT, Neurological Technologies, Navigation and Advanced Energy. The ENT products treat diseases and conditions, such as NIM Nerve Monitoring Systems, Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for Meniere's Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive Sleep Apnea. The Neurological Technologies products treat certain neurological disorders and conditions, such as Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.

The Navigation products are used in cranial, spinal, sinus, and orthopedic surgeries, such as the StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging System, and the PoleStar Surgical MRI System. The products make up the Advanced Energy business: PEAK Surgery System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and the Aquamantys System, which uses patented Transcollation technology to ! provide h! aemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.

The Company competes with Gyrus ACMI, Stryker Corporation, Johnson & Johnson, Integra LifeSciences Holdings Corporation, BrainLAB, Inc., GE Healthcare, Siemens Medical Solutions USA, Inc., Philips Medical Systems, Covidien and ArthroCare Corporation.

Advisors' Opinion:

• [By James Brumley]

  At the extreme other end of the spectrum are medical device makers like Medtronics (MDT) and Stryker (SYK).

  These companies have already been crimped by Obamacare’s 2.3% excise tax (which went into effect at the beginning of this year) on certain medical devices in order to fund most of the act’s implementation. The tax reportedly costs the industry more than $2.5 billion per year, but medical device makers’ stocks are up a decent 13% since the end of 2012.

• [By Sean Williams]

  The pure play, as I see it, is Medtronic (NYSE: MDT  ) , which is a global leader in cardiovascular and spinal implants. This device maker can claim annual revenue growth in every year over the past decade, along with gross margins that have moved within a tight 180-basis-point range and hit a decade high in 2012. In the company's third-quarter results, announced in February, it demonstrated growth across all regions -- domestic, international, and emerging markets -- while delivering free cash flow of $1.4 billion. It's definitely a company whose product line can be set on cruise control.

• [By Dan Carroll]

  St. Jude's sales slipped again in this area in its most recent quarterly report, falling 8% -- a bad sign for the company considering that CRM revenue makes up the foundation of its sales. Pacemaker sales in particular nosedived, dropping 12%. It isn't any easier across the industry: Boston Scientific (NYSE: BSX  ) , which made the majority of its revenue from cardiac products last year, saw sales in its interventional cardiology and CRM businesses fall 11% and 7%, respectively, at a constant currency in 2012. Rival Medtronic (NYSE: MDT  ) , the largest purely medical device maker on the market, managed to eke out gains in its cardiac and vascular group over the last nine months but still lost 6% in cardiac rhythm disease management sales.

• [By The Part-time Investor]

  Due to the sale of stocks that cut their dividend (and buyouts), and reinvestment of this money into new positions, In January of 2009 the following three new stocks were purchased.

  Dover Corp. (DOV)Johnson Controls (JCI)Medtronics (MDT)

  In January of 2010, again, due to stock sales (and buyouts) a further four new stocks were bought.

10 Best Medical Stocks To Watch For 2015: Intercept Pharmaceuticals Inc (ICPT)

Intercept Pharmaceuticals, Inc., incorporated on September 4, 2002, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�� product candidates treat orphan and more prevalent liver diseases for which there are limited therapeutic solutions. The Company�� product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.

The Company�� clinical focus is on the development of OCA, orally administered, first-in-class FXR agonist that has broad liver-protective properties and may a variety of chronic insults to the liver that cause fibrosis, which can eventually lead to cirrhosis, liver transplant and death. The Company owns worldwide rights to OCA outside of Japan and China, where it has licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to license OCA in certain other Asian countries.The Company is sponsoring an independent study involving more than ten leading PBC centers in North America and Europe, or collectively the Global PBC Study Group, that are pooling their long-term patient data to evaluate the relationship between biochemical and clinical endpoints.

The Company competes with Eli Lilly, Exelixis, Inc., Phenex Pharmaceuticals AG, , Johnson & Johnson, NovImmune SA, Dr. Falk Pharma GmbH, Galmed Medical Researc! h Ltd., Immuron Ltd., Mochida Pharmaceutical Co., Ltd., NasVax Ltd. , Raptor Pharmaceutical Corp. Astellas Pharma US, Inc., AstraZeneca, Salix Pharmaceuticals, Inc. and Tioga Pharmaceuticals, Inc.

Advisors' Opinion:

• [By Ben Levisohn]

  I mean, just look at these returns: Gilead Sciences (GILD) has gained 41% so far this year as investors appear to have put their Sovaldi worries behind them; InterMune (ITMN) has quintupled in 2014 after Roche agreed to purchase it for $8.3 billion; and Intercept Pharmaceuticals (ICPT) has surged 350% as drug trials have been surprisingly good. All told, the iShares Nasdaq Biotechnology ETF (IBB) has risen 21%, more than double the S&P 500′s 8.3% rise.

10 Best Medical Stocks To Watch For 2015: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

10 Best Medical Stocks To Watch For 2015: Portola Pharmaceuticals Inc (PTLA)

Portola Pharmaceuticals, Inc. (Portola), incorporated on September 2, 2003, is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology. The Company is advancing its three wholly owned programs using biomarker and genetic approaches.

Betrixaban

Portola's compound, betrixaban, is an oral, once-daily Factor Xa inhibitor being evaluated in the only biomarker-based Phase-III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's properties particularly suited to potentially demonstrate efficacy without increasing bleeding in this patient population.

Andexanet Alfa

Portola's second development candidate, andexanet alfa (PRT4445), has the potential to be a reversal agent to directly reverse the effects of Factor Xa inhibitors in patients who suffer a bleeding episode or who require emergency surgery. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb and Pfizer (Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO [rivaroxaban]), and Daiichi Sankyo (Savaysa [edoxaban]), while retaining all decision-making and commercial rights to the program.

Cerdulatinib (PRT2070) and PRT2607

Portola's third wholly owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways - spleen tyrosine kinase (Syk) and janus kinase (JAK). It is being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor.

Advisors' Opinion:

• [By Todd Campbell]

  That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.